These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17826412

  • 21. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA, Mrinalini C.
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery.
    Sibai B, Meis PJ, Klebanoff M, Dombrowski MP, Weiner SJ, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, Maternal Fetal Medicine Units Network of the National Institute of Child Health and Human Development.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1181-6. PubMed ID: 16157134
    [Abstract] [Full Text] [Related]

  • 30. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL, Walker HC, Hade EM, Iams JD.
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 33. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
    O'Brien JM, Ho SJ, Istwan NB, Stanziano GJ, Rhea DJ, Barton JR.
    Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pregnancy outcomes in a recurrent preterm birth prevention clinic.
    Manuck TA, Henry E, Gibson J, Varner MW, Porter TF, Jackson GM, Esplin MS.
    Am J Obstet Gynecol; 2011 Apr; 204(4):320.e1-6. PubMed ID: 21345407
    [Abstract] [Full Text] [Related]

  • 36. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Feghali M, Boyle A, Istwan N, Rhea D, Driggers RW.
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [Abstract] [Full Text] [Related]

  • 37. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
    Rebarber A, Fox NS, Klauser CK, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
    [Abstract] [Full Text] [Related]

  • 38. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM, Vladutiu CJ, Manuck T, Verbiest S, Ollendorff A, Stringer JS, Menard MK.
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [Abstract] [Full Text] [Related]

  • 39. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Singh J, Istwan N, Rhea D, Driggers RW.
    Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
    [Abstract] [Full Text] [Related]

  • 40. 17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days.
    Mason MV, House KM, Fuest CM, Fitzgerald DR, Kitson BJ, Inglis JA.
    Manag Care; 2005 Oct; 14(10):58-63. PubMed ID: 16277194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.